Arcturus Therapeutics Holdings Inc.
ARCT
$10.53
$0.232.23%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -8.69% | -45.85% | -38.04% | -55.69% | -19.03% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -8.69% | -45.85% | -38.04% | -55.69% | -19.03% |
| Cost of Revenue | -2.19% | -0.50% | 20.53% | -6.74% | -3.08% |
| Gross Profit | -48.10% | -83.10% | -86.82% | -115.57% | -59.50% |
| SG&A Expenses | -0.09% | 1.39% | 3.34% | 9.89% | 14.76% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 0.89% | 2.31% | 14.40% | 21.29% | 26.41% |
| Operating Income | -21.31% | -229.63% | -300.62% | -258.54% | -742.24% |
| Income Before Tax | -190.23% | -161.04% | -185.81% | -193.37% | -362.03% |
| Income Tax Expenses | -100.16% | -90.83% | -30.48% | 50.21% | 41.70% |
| Earnings from Continuing Operations | -172.30% | -163.07% | -189.63% | -196.43% | -417.95% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -172.30% | -163.07% | -189.63% | -196.43% | -417.95% |
| EBIT | -21.31% | -229.63% | -300.62% | -258.54% | -742.24% |
| EBITDA | -21.37% | -218.68% | -283.27% | -250.63% | -649.10% |
| EPS Basic | -168.80% | -162.16% | -188.73% | -196.09% | -430.08% |
| Normalized Basic EPS | -27.78% | -188.84% | -242.87% | -232.17% | -700.87% |
| EPS Diluted | -158.78% | -164.56% | -192.91% | -199.32% | -565.17% |
| Normalized Diluted EPS | -27.01% | -192.75% | -251.92% | -237.20% | -899.84% |
| Average Basic Shares Outstanding | 1.49% | 1.26% | 0.90% | 0.65% | 0.51% |
| Average Diluted Shares Outstanding | 0.93% | 0.16% | -0.20% | -0.45% | 0.53% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |